Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + pembrolizumab
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous
01
Overview
Efineptakin alfa + pembrolizumab is a combination therapy being investigated for various cancer types. Efineptakin alfa (NT-I7, GX-I7) is the only clinical stage long-acting human interleukin-7 (IL-7), a fundamental cytokine involved in T cell development that helps sustain immune response to chronic antigens. It is designed to increase T cell infiltration in the tumor microenvironment. Pembrolizumab (Keytruda) is a PD-1 checkpoint inhibitor that helps restore the immune functions of T cells, enabling the body to recognize cancer cells as foreign and kill them. The combination aims to enhance anti-tumor activity, particularly in "cold" tumors that are typically resistant to single immunotherapeutic agents.
- Brand names
- Keytruda
- Other names
- GX-I7 + pembrolizumabefineptakin alfa + pembrolizumab
02
Targets
IL7R (Interleukin-7 Receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on efineptakin alfa + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + pembrolizumab.